Paiola, M., Portnoy, D. M., Hao, L. Y., Bukhari, S., Winchester, R. J., Henick, B. S., Mor, A., & Gartshteyn, Y. (2025). Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells. Journal for ImmunoTherapy of Cancer, 13(3), e010758. https://doi.org/10.1136/jitc-2024-010758

Varanasi, S. K., Chen, D., Liu, Y., Johnson, M. A., Miller, C. M., Ganguly, S., Lande, K., LaPorta, M. A., Hoffmann, F. A., Mann, T. H., Teneche, M. G., Casillas, E., Mangalhara, K. C., Mathew, V., Sun, M., Jensen, I. J., Farsakoglu, Y., Chen, T., Parisi, B., … Kaech, S. M. (2025). Bile acid synthesis impedes tumor-specific T cell responses during liver cancer. Science, 387(6730), 192–201. https://doi.org/10.1126/science.adl4100

Dimitriou, F., Orloff, M. M., Koch Hein, E. C., Cheng, P. F., Hughes, I. F., Simeone, E., Montazeri, K., Grover, P., Mehmi, I., Gerard, C. L., Gaudy-Marqueste, C., Grob, J.-J., Michielin, O., Hamid, O., Long, G. V., Sullivan, R., Kapiteijn, E., Johnson, D. B., Ascierto, P. A., … Dummer, R. (2025). Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. European Journal of Cancer, 214, 115161. https://doi.org/10.1016/j.ejca.2024.115161

Ma, K. L., Mitchell, T. C., Dougher, M., Sharon, C. E., Tortorello, G. N., Elder, D. E., Morgan, E. E., Gimotty, P. A., Huang, A. C., Amaravadi, R. K., Schuchter, L. M., Flowers, A., Miura, J. T., Karakousis, G. C., & Xu, X. (2024). Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti–PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival. Clinical Cancer Research, 30(21), 4987–4994. https://doi.org/10.1158/1078-0432.ccr-23-3775

Rashidi, A., Shah, C., & Sekulic, M. (2022). The Role of Kidney Biopsy in Immune Checkpoint Inhibitor-Associated AKI. Kidney360, 3(3), 530–533. https://doi.org/10.34067/kid.0000232022

Schöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., De Braud, F., Hui, R., Zhang, T., Soo, R. A., Maur, M., Weickhardt, A., Krauss, J., Deschler-Baier, B., Lau, A., … Hong, D. S. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for ImmunoTherapy of Cancer, 10(2), e003776. https://doi.org/10.1136/jitc-2021-003776

Palmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022). Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. Clinical Cancer Research, 28(2), 368–377. https://doi.org/10.1158/1078-0432.ccr-21-2275

Doshi, S. D., Oza, J., Remotti, H., Remotti, F., Moy, M. P., Schwartz, G. K., & Ingham, M. (2021). Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation-Associated Sarcoma. JCO Precision Oncology, 5, 1–5. https://doi.org/10.1200/po.20.00201